These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 34452312)

  • 21. Paradoxical role of antibodies in dengue virus infections: considerations for prophylactic vaccine development.
    Acosta EG; Bartenschlager R
    Expert Rev Vaccines; 2016; 15(4):467-82. PubMed ID: 26577689
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Focused dengue vaccine development: outwitting nature's design.
    Kudlacek ST; Metz SW
    Pathog Dis; 2019 Feb; 77(1):. PubMed ID: 30726906
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term stability of antibody responses elicited by Dengue virus envelope DIII-based DNA vaccines.
    Slon Campos JL; Poggianella M; Burrone OR
    J Gen Virol; 2018 Aug; 99(8):1078-1085. PubMed ID: 29923817
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimization of Surface Display of DENV2 E Protein on a Nanoparticle to Induce Virus Specific Neutralizing Antibody Responses.
    Coffman JE; Metz SW; Brackbill A; Paul M; Miley MJ; DeSimone J; Luft JC; de Silva A; Tian S
    Bioconjug Chem; 2018 May; 29(5):1544-1552. PubMed ID: 29701995
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structural perspectives of antibody-dependent enhancement of infection of dengue virus.
    Morrone SR; Lok SM
    Curr Opin Virol; 2019 Jun; 36():1-8. PubMed ID: 30844538
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular basis of dengue virus serotype 2 morphological switch from 29°C to 37°C.
    Lim XN; Shan C; Marzinek JK; Dong H; Ng TS; Ooi JSG; Fibriansah G; Wang J; Verma CS; Bond PJ; Shi PY; Lok SM
    PLoS Pathog; 2019 Sep; 15(9):e1007996. PubMed ID: 31536610
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neutralization of antibody-enhanced dengue infection by VIS513, a pan serotype reactive monoclonal antibody targeting domain III of the dengue E protein.
    Budigi Y; Ong EZ; Robinson LN; Ong LC; Rowley KJ; Winnett A; Tan HC; Hobbie S; Shriver Z; Babcock GJ; Alonso S; Ooi EE
    PLoS Negl Trop Dis; 2018 Feb; 12(2):e0006209. PubMed ID: 29425203
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of single-round infectious, chimeric dengue type 1 virus as an antigen for dengue functional antibody assays.
    Yamanaka A; Suzuki R; Konishi E
    Vaccine; 2014 Jul; 32(34):4289-95. PubMed ID: 24950360
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Precisely Molded Nanoparticle Displaying DENV-E Proteins Induces Robust Serotype-Specific Neutralizing Antibody Responses.
    Metz SW; Tian S; Hoekstra G; Yi X; Stone M; Horvath K; Miley MJ; DeSimone J; Luft CJ; de Silva AM
    PLoS Negl Trop Dis; 2016 Oct; 10(10):e0005071. PubMed ID: 27764114
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Functional Transplant of a Dengue Virus Serotype 3 (DENV3)-Specific Human Monoclonal Antibody Epitope into DENV1.
    Messer WB; Yount BL; Royal SR; de Alwis R; Widman DG; Smith SA; Crowe JE; Pfaff JM; Kahle KM; Doranz BJ; Ibarra KD; Harris E; de Silva AM; Baric RS
    J Virol; 2016 May; 90(10):5090-5097. PubMed ID: 26962223
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity.
    Khanam S; Pilankatta R; Khanna N; Swaminathan S
    Vaccine; 2009 Oct; 27(43):6011-21. PubMed ID: 19665609
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of Dengue Virus Serotype 2 Strain Diversity on Serological Immune Responses to Dengue.
    Keasey SL; Smith JL; Fernandez S; Durbin AP; Zhao BM; Ulrich RG
    ACS Infect Dis; 2018 Dec; 4(12):1705-1717. PubMed ID: 30347144
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of Adeno-associated viral vectors to improve delivery of a DNA vaccine against dengue virus.
    Slon-Campos JL; Poggianella M; Zentilin L; Burrone OR
    J Gen Virol; 2020 Jan; 101(1):73-78. PubMed ID: 31702541
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein.
    VanBlargan LA; Mukherjee S; Dowd KA; Durbin AP; Whitehead SS; Pierson TC
    PLoS Pathog; 2013; 9(12):e1003761. PubMed ID: 24348242
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dengue virus envelope domain III immunization elicits predominantly cross-reactive, poorly neutralizing antibodies localized to the AB loop: implications for dengue vaccine design.
    Li XQ; Qiu LW; Chen Y; Wen K; Cai JP; Chen J; Pan YX; Li J; Hu DM; Huang YF; Liu LD; Ding XX; Guo YH; Che XY
    J Gen Virol; 2013 Oct; 94(Pt 10):2191-2201. PubMed ID: 23851440
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comprehensive mapping of functional epitopes on dengue virus glycoprotein E DIII for binding to broadly neutralizing antibodies 4E11 and 4E5A by phage display.
    Frei JC; Kielian M; Lai JR
    Virology; 2015 Nov; 485():371-82. PubMed ID: 26339794
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of Individuals from a Dengue-Endemic Region Helps Define the Footprint and Repertoire of Antibodies Targeting Dengue Virus 3 Type-Specific Epitopes.
    Andrade DV; Katzelnick LC; Widman DG; Balmaseda A; de Silva AM; Baric RS; Harris E
    mBio; 2017 Sep; 8(5):. PubMed ID: 28928210
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Live attenuated tetravalent dengue virus host range vaccine is immunogenic in African green monkeys following a single vaccination.
    Briggs CM; Smith KM; Piper A; Huitt E; Spears CJ; Quiles M; Ribeiro M; Thomas ME; Brown DT; Hernandez R
    J Virol; 2014 Jun; 88(12):6729-42. PubMed ID: 24696467
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular Simulations Reveal the Role of Antibody Fine Specificity and Viral Maturation State on Antibody-Dependent Enhancement of Infection in Dengue Virus.
    Ripoll DR; Wallqvist A; Chaudhury S
    Front Cell Infect Microbiol; 2019; 9():200. PubMed ID: 31275864
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tests in mice of a dengue vaccine candidate made of chimeric Junin virus-like particles and conserved dengue virus envelope sequences.
    Mareze VA; Borio CS; Bilen MF; Fleith R; Mirazo S; Mansur DS; Arbiza J; Lozano ME; Bruña-Romero O
    Appl Microbiol Biotechnol; 2016 Jan; 100(1):125-33. PubMed ID: 26386688
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.